ThermoGenesis Holdings Announces Adjournment of Annual Meeting of Stockholders

Rhea-AI Summary

ThermoGenesis Holdings, Inc. (THMO) announced that its Annual Meeting of Stockholders, initially set for December 16, 2021, was adjourned due to a lack of quorum. Fewer than the majority of shares entitled to vote were present. The meeting will reconvene on January 13, 2022, allowing more time for stockholders to vote on proposals outlined in the Proxy Statement filed with the SEC on November 5, 2021. Stockholders are encouraged to vote by January 12, 2022. Proxies submitted will remain valid unless revoked.

Positive

• The company has rescheduled the Annual Meeting for January 13, 2022, indicating ongoing efforts to ensure stockholder participation.

Negative

• The adjournment indicates a lack of engagement from stockholders, as only approximately 49.39% of shares were present or proxy-voted.

RANCHO CORDOVA, Calif., Dec. 17, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), announced that the Company's Annual Meeting of Stockholders (the "Annual Meeting") scheduled for Thursday, December 16, 2021 at 9:00 a.m. PST, was convened and adjourned without any business being conducted due to lack of the required quorum.

A quorum consists of a majority of the shares entitled to vote. There were fewer than a majority of shares entitled to vote present, either in person or by proxy, at the convening of the Annual Meeting. The Annual Meeting therefore had no quorum and the meeting was adjourned until 9:00 a.m. PST on Thursday, January 13, 2022 at 2711 Citrus Rd., Rancho Cordova, CA 95742 to allow additional time for the Company's stockholders to vote on the proposals set forth in the Company's definitive proxy statement filed with the United States Securities and Exchange Commission (the "SEC") on November 5, 2021 (the "Proxy Statement"). A conference call and webcast will be available.  To participate in the conference call, please dial 1-844-889-4331 (domestic), 1-412-380-7406 (international) or 1-866-605-3852 (Canada). To access a live webcast of the call, please visit: https://thermogenesis.com/investors/news-and-events/events-webcasts.

During the current adjournment, the Company continues to solicit votes from its stockholders with respect to the proposals set forth in the Company's Proxy Statement.

Only stockholders of record as of the record date, October 26, 2021, are entitled to and are being requested to vote. At the time the Annual Meeting was adjourned, proxies had been submitted by stockholders representing approximately 49.39% of the shares of the Company's common stock outstanding and entitled to vote at the Annual Meeting. Proxies previously submitted in respect of the Annual Meeting will be voted at the adjourned Annual Meeting unless properly revoked, and stockholders who have previously submitted a proxy or otherwise voted need not take any action.

The Company encourages all stockholders of record on October 26, 2021, who have not yet voted, to do so by January 12, 2022. Stockholders who have any questions or require any assistance with completing a proxy or voting instruction form or who do not have the required materials may contact the Company at (916) 858-5100 or by emailing ir@thermogenesis.com.

Important Information
This material may be deemed to be solicitation material in respect of the Annual Meeting to be reconvened on January 13, 2022. In connection with the Annual Meeting, the Company filed the Proxy Statement. BEFORE MAKING ANY VOTING DECISIONS, SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING. No changes have been made in the proposals to be voted on by stockholders at the Annual Meeting. The Company's Proxy Statement and any other materials filed by the Company with the SEC can be obtained free of charge at the SEC's website at sec.gov or the Company's website at thermogenesis.com.

About ThermoGenesis Holdings, Inc.
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. For more information about ThermoGenesis, please visit: www.thermogenesis.com.

Company Contact:
Wendy Samford
916-858-5191
ir@ThermoGenesis.com

Investor Contact:
Paula Schwartz, Rx Communications
917-322-2216
pschwartz@rxir.com

 

View original content:https://www.prnewswire.com/news-releases/thermogenesis-holdings-announces-adjournment-of-annual-meeting-of-stockholders-301447632.html

SOURCE ThermoGenesis Holdings, Inc.

FAQ

What happened at ThermoGenesis Holdings' Annual Meeting on December 16, 2021?

The Annual Meeting was adjourned due to a lack of quorum, meaning not enough stockholders were present to conduct business.

When is the rescheduled Annual Meeting for ThermoGenesis Holdings?

The rescheduled Annual Meeting is set for January 13, 2022, at 9:00 a.m. PST.

What percentage of shares were represented at the adjourned Annual Meeting of ThermoGenesis Holdings?

Approximately 49.39% of the shares entitled to vote were represented at the adjourned Annual Meeting.

What should stockholders do before the new voting deadline for ThermoGenesis Holdings?

Stockholders are encouraged to vote by January 12, 2022, if they have not yet done so.

How can stockholders participate in the rescheduled Annual Meeting for ThermoGenesis Holdings?

Stockholders can participate by attending the meeting in person or via conference call and webcast.